Matches in SemOpenAlex for { <https://semopenalex.org/work/W2795000582> ?p ?o ?g. }
Showing items 1 to 92 of
92
with 100 items per page.
- W2795000582 abstract "TPS524 Background: Olaratumab is a human IgG1 monoclonal antibody that specifically binds human platelet-derived growth factor receptor (PDGFR)-α and blocks PDGF-mediated signaling pathways. Increased PDGFRα expression is observed in pancreatic cancer tissue, and has been suggested to play a role in the mesenchymal transition of pancreatic cancer. An ongoing trial designed to evaluate the safety and efficacy of olaratumab in combination with nab-paclitaxel/gemcitabine (nPG) in patients with unresectable metastatic pancreatic cancer not previously treated for metastatic disease is currently being conducted. Methods: JGDP (NCT03086369) is a global Phase 1b/Phase 2 study being conducted to evaluate the safety and efficacy of olaratumab in combination with nPG as first-line therapy in patients with Stage IV pancreatic cancer (ECOG PS ≤1). In the Phase 1b portion of the study, patients will receive intravenous (iv) olaratumab following a 3+3 dose escalation scheme at two different schedules: on Days 1, 8 and 15 at doses of 15 mg/kg and 20 mg/kg, or on Days 1 and 15 at 20 mg/kg and 25 mg/kg. Olaratumab will be given in combination with nPG (125 mg/m 2 iv/1000 mg/m 2 iv) on Days 1, 8, and 15 of a 28-day cycle. After the maximum tolerated dose has been identified, additional patients will be enrolled in a cohort expansion to confirm the safety of the combination prior to proceeding to the Phase 2 portion of the study. In the Phase 2 study, approximately 162 patients will be randomized at a 1:1 ratio to receive olaratumab at the recommended Phase 2 dose regimen or placebo, both in combination with nPG (125 mg/m 2 iv/1000 mg/m 2 iv). Treatment will continue until disease progression or other discontinuation criteria are met. The primary end point of the Phase 2 study is overall survival; a 2-sided α level of 0.20 will be applied. Assuming OS HR = 0.67, there is ≥80% power to show a significant difference in OS between study arms. Secondary end points include progression free survival, duration of response, objective response rate, patient-reported outcomes, and safety. As of September 2017, enrollment for the Phase 1b study is currently ongoing. Clinical trial information: NCT03086369." @default.
- W2795000582 created "2018-04-06" @default.
- W2795000582 creator A5001201465 @default.
- W2795000582 creator A5005756097 @default.
- W2795000582 creator A5006886614 @default.
- W2795000582 creator A5008124413 @default.
- W2795000582 creator A5014629130 @default.
- W2795000582 creator A5028472820 @default.
- W2795000582 creator A5029563022 @default.
- W2795000582 creator A5049306094 @default.
- W2795000582 creator A5070523850 @default.
- W2795000582 creator A5073785005 @default.
- W2795000582 creator A5084149387 @default.
- W2795000582 creator A5086242280 @default.
- W2795000582 date "2018-02-01" @default.
- W2795000582 modified "2023-10-18" @default.
- W2795000582 title "A phase 1b (open-label)/phase 2 (randomized, double-blinded) study evaluating nab-paclitaxel and gemcitabine with or without olaratumab in first-line treatment of metastatic pancreatic cancer." @default.
- W2795000582 doi "https://doi.org/10.1200/jco.2018.36.4_suppl.tps524" @default.
- W2795000582 hasPublicationYear "2018" @default.
- W2795000582 type Work @default.
- W2795000582 sameAs 2795000582 @default.
- W2795000582 citedByCount "0" @default.
- W2795000582 crossrefType "journal-article" @default.
- W2795000582 hasAuthorship W2795000582A5001201465 @default.
- W2795000582 hasAuthorship W2795000582A5005756097 @default.
- W2795000582 hasAuthorship W2795000582A5006886614 @default.
- W2795000582 hasAuthorship W2795000582A5008124413 @default.
- W2795000582 hasAuthorship W2795000582A5014629130 @default.
- W2795000582 hasAuthorship W2795000582A5028472820 @default.
- W2795000582 hasAuthorship W2795000582A5029563022 @default.
- W2795000582 hasAuthorship W2795000582A5049306094 @default.
- W2795000582 hasAuthorship W2795000582A5070523850 @default.
- W2795000582 hasAuthorship W2795000582A5073785005 @default.
- W2795000582 hasAuthorship W2795000582A5084149387 @default.
- W2795000582 hasAuthorship W2795000582A5086242280 @default.
- W2795000582 hasConcept C121608353 @default.
- W2795000582 hasConcept C126322002 @default.
- W2795000582 hasConcept C143998085 @default.
- W2795000582 hasConcept C168563851 @default.
- W2795000582 hasConcept C2775930923 @default.
- W2795000582 hasConcept C2776694085 @default.
- W2795000582 hasConcept C2777292972 @default.
- W2795000582 hasConcept C2777844706 @default.
- W2795000582 hasConcept C2780210213 @default.
- W2795000582 hasConcept C2780258809 @default.
- W2795000582 hasConcept C2910430875 @default.
- W2795000582 hasConcept C3019800554 @default.
- W2795000582 hasConcept C31760486 @default.
- W2795000582 hasConcept C530470458 @default.
- W2795000582 hasConcept C71924100 @default.
- W2795000582 hasConceptScore W2795000582C121608353 @default.
- W2795000582 hasConceptScore W2795000582C126322002 @default.
- W2795000582 hasConceptScore W2795000582C143998085 @default.
- W2795000582 hasConceptScore W2795000582C168563851 @default.
- W2795000582 hasConceptScore W2795000582C2775930923 @default.
- W2795000582 hasConceptScore W2795000582C2776694085 @default.
- W2795000582 hasConceptScore W2795000582C2777292972 @default.
- W2795000582 hasConceptScore W2795000582C2777844706 @default.
- W2795000582 hasConceptScore W2795000582C2780210213 @default.
- W2795000582 hasConceptScore W2795000582C2780258809 @default.
- W2795000582 hasConceptScore W2795000582C2910430875 @default.
- W2795000582 hasConceptScore W2795000582C3019800554 @default.
- W2795000582 hasConceptScore W2795000582C31760486 @default.
- W2795000582 hasConceptScore W2795000582C530470458 @default.
- W2795000582 hasConceptScore W2795000582C71924100 @default.
- W2795000582 hasLocation W27950005821 @default.
- W2795000582 hasOpenAccess W2795000582 @default.
- W2795000582 hasPrimaryLocation W27950005821 @default.
- W2795000582 hasRelatedWork W2233934361 @default.
- W2795000582 hasRelatedWork W2243767710 @default.
- W2795000582 hasRelatedWork W2259954909 @default.
- W2795000582 hasRelatedWork W2260857453 @default.
- W2795000582 hasRelatedWork W2268972469 @default.
- W2795000582 hasRelatedWork W2464744894 @default.
- W2795000582 hasRelatedWork W2470132378 @default.
- W2795000582 hasRelatedWork W2493117159 @default.
- W2795000582 hasRelatedWork W2588419981 @default.
- W2795000582 hasRelatedWork W2590409500 @default.
- W2795000582 hasRelatedWork W2593521549 @default.
- W2795000582 hasRelatedWork W2598040025 @default.
- W2795000582 hasRelatedWork W2890855868 @default.
- W2795000582 hasRelatedWork W2912591847 @default.
- W2795000582 hasRelatedWork W2913333595 @default.
- W2795000582 hasRelatedWork W2965985902 @default.
- W2795000582 hasRelatedWork W3031469608 @default.
- W2795000582 hasRelatedWork W3032186706 @default.
- W2795000582 hasRelatedWork W3124944127 @default.
- W2795000582 hasRelatedWork W3172654382 @default.
- W2795000582 isParatext "false" @default.
- W2795000582 isRetracted "false" @default.
- W2795000582 magId "2795000582" @default.
- W2795000582 workType "article" @default.